CorMedix Inc $CRMD Stock Position Lifted by Quantinno Capital Management LP

Quantinno Capital Management LP grew its position in CorMedix Inc (NASDAQ:CRMD) by 1,006.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 124,909 shares of the company’s stock after acquiring an additional 113,619 shares during the quarter. Quantinno Capital Management LP owned approximately 0.16% of CorMedix worth $848,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of CorMedix by 13.1% in the 4th quarter. Vanguard Group Inc. now owns 4,499,010 shares of the company’s stock worth $52,323,000 after buying an additional 521,352 shares during the last quarter. Private Advisor Group LLC grew its position in shares of CorMedix by 33.3% during the 1st quarter. Private Advisor Group LLC now owns 504,668 shares of the company’s stock valued at $3,427,000 after buying an additional 126,131 shares during the last quarter. Del Sette Capital Management LLC acquired a new stake in CorMedix during the fourth quarter worth about $2,452,000. Round Rock Advisors LLC acquired a new stake in CorMedix during the fourth quarter worth about $1,044,000. Finally, Sanctuary Advisors LLC lifted its holdings in CorMedix by 1,050.2% in the fourth quarter. Sanctuary Advisors LLC now owns 134,669 shares of the company’s stock worth $1,566,000 after acquiring an additional 122,961 shares during the last quarter. 34.18% of the stock is owned by institutional investors and hedge funds.

CorMedix Price Performance

NASDAQ CRMD opened at $7.67 on Tuesday. The company has a 50-day moving average price of $8.12 and a two-hundred day moving average price of $7.64. CorMedix Inc has a 52 week low of $6.13 and a 52 week high of $14.96. The stock has a market cap of $597.80 million, a price-to-earnings ratio of 3.58 and a beta of 1.50. The company has a current ratio of 2.56, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31.

CorMedix (NASDAQ:CRMD) last released its quarterly earnings results on Thursday, August 13th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. CorMedix had a return on equity of 40.52% and a net margin of 40.49%.The company had revenue of $101.93 million for the quarter, compared to analysts’ expectations of $96.04 million. Analysts forecast that CorMedix Inc will post 0.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on CRMD shares. Zacks Research raised CorMedix from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Citizens Jmp restated a “market outperform” rating and set a $19.00 price objective on shares of CorMedix in a research report on Tuesday, April 28th. D. Boral Capital restated a “buy” rating and set a $14.00 price objective on shares of CorMedix in a research note on Monday, April 27th. Royal Bank Of Canada increased their target price on CorMedix from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Needham & Company LLC raised their target price on CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, CorMedix currently has an average rating of “Moderate Buy” and an average price target of $15.00.

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.